Cargando…

Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer

PURPOSE: To evaluate safety of TAS-102 administered twice daily (bid) on days 1–5 and 8–12 of a 4-week cycle, confirm feasibility of the Japanese recommended dose (RD), 35 mg/m(2), in Western patients with metastatic colorectal cancer (mCRC) refractory to standard chemotherapies, and describe prelim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bendell, Johanna C., Rosen, Lee S., Mayer, Robert J., Goldman, Jonathan W., Infante, Jeffrey R., Benedetti, Fabio, Lin, Donghu, Mizuguchi, Hirokazu, Zergebel, Christopher, Patel, Manish R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612319/ https://www.ncbi.nlm.nih.gov/pubmed/26370544 http://dx.doi.org/10.1007/s00280-015-2850-4

Ejemplares similares

Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
por: Bendell, Johanna C., et al.
Publicado: (2015)

Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis
por: Chen, Duke, et al.
Publicado: (2018)

Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study
por: Conti, Matteo, et al.
Publicado: (2023)

Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
por: Sugiura, Kiyoaki, et al.
Publicado: (2021)

Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors
por: Bendell, Johanna C., et al.
Publicado: (2016)

A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer
por: Su, Guan-Li, et al.
Publicado: (2020)

A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Chen, Xiaochen, et al.
Publicado: (2021)

TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
por: Liu, Cheng-Jiang, et al.
Publicado: (2021)

Bevacizumab in Combination with TAS‐102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study
por: Fujii, Hironori, et al.
Publicado: (2019)

Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
por: Huemer, Florian, et al.
Publicado: (2020)

TAS-102 and the quest for predictive biomarkers
por: van der Velden, Daphne L, et al.
Publicado: (2017)

Interstitial pneumonia in a patient treated with TAS-102 for metastatic colorectal cancer: a case report
por: Kamei, Hideki, et al.
Publicado: (2016)

TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?
por: Petrelli, Fausto, et al.
Publicado: (2016)

Phase Ib/II Study of Biweekly TAS‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)
por: Satake, Hironaga, et al.
Publicado: (2020)

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study
por: Kasi, Pashtoon M., et al.
Publicado: (2016)

Drug-induced Pneumonitis Following the Administration of TAS-102
por: Hasegawa, Yoshikazu, et al.
Publicado: (2016)

Difference in Neutropenia due to Administration Schedule of TAS-102
por: Yoshida, Yoichiro, et al.
Publicado: (2017)

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer
por: Van Cutsem, Eric, et al.
Publicado: (2017)

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2019)

Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with (90)Y resin microspheres for chemo-refractory colorectal liver metastases
por: Fidelman, Nicholas, et al.
Publicado: (2022)

Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer
por: Doi, Toshihiko, et al.
Publicado: (2015)

Feasibility of 7-T fluorine magnetic resonance spectroscopic imaging ((19)F MRSI) for TAS-102 metabolite detection in the liver of patients with metastatic colorectal cancer
por: Kurk, Sophie A., et al.
Publicado: (2018)

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial
por: Longo-Muñoz, F., et al.
Publicado: (2016)

Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme
por: Sforza, Vincenzo, et al.
Publicado: (2017)

TAS-102 in metastatic colorectal cancer (mCRC): efficacy, tolerability, and quality of life in heavily pretreated elderly patients: a real-life study
por: Cicero, Giuseppe, et al.
Publicado: (2020)

Prophylactic use of pegfilgrastim enables the management of severe neutropenia without dose delays in patients with metastatic colorectal cancer treated with TAS-102 plus bevacizumab
por: Tamaki, Sawako, et al.
Publicado: (2022)

Survival and Toxicities of Metastatic Colorectal Cancer Patients Treated with Regorafenib before TAS-102 or Vice Versa: A Mono-Institutional Real-Practice Study
por: Ottaiano, Alessandro, et al.
Publicado: (2023)

Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report
por: Li, Qizheng, et al.
Publicado: (2022)

Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials
por: Chen, Jianxin, et al.
Publicado: (2019)

Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias
por: Watanabe, Daichi, et al.
Publicado: (2023)

A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite‐stable metastatic colorectal cancer
por: Patel, Manish R., et al.
Publicado: (2021)

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours
por: Doi, T, et al.
Publicado: (2012)

A Trial Protocol of Biweekly TAS-102 and Bevacizumab as Third-Line Chemotherapy for Advanced/Recurrent Colorectal Cancer: A Phase II Multicenter Clinical Trial (The TAS-CC4 Study)
por: Yoshida, Yoichiro, et al.
Publicado: (2019)

Effect of food on the pharmacokinetics of TAS‐102 and its efficacy and safety in patients with advanced solid tumors
por: Yoshino, Takayuki, et al.
Publicado: (2016)

A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone
por: Cleary, James M., et al.
Publicado: (2017)

Complete response to third-line treatment with trifluridine/tipiracil (TAS-102) in stage IV colon adenocarcinoma
por: Lara-Morga, Celia, et al.
Publicado: (2023)

Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts
por: TSUKIHARA, HIROSHI, et al.
Publicado: (2015)

MBD4 frameshift mutation caused by DNA mismatch repair deficiency enhances cytotoxicity by trifluridine, an active antitumor agent of TAS-102, in colorectal cancer cells
por: Suzuki, Satoshi, et al.
Publicado: (2017)

Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models
por: TANAKA, NOZOMU, et al.
Publicado: (2014)

Panitumumab interaction with TAS‐102 leads to combinational anticancer effects via blocking of EGFR‐mediated tumor response to trifluridine
por: Baba, Yuji, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_38hh77ajb73fkdk7sdlr8a0jes